Zymeworks Competitors

Stocks . USA . 
Stock . Zymeworks Common Stock
ZYME Stock  USD 22.55  0.17  0.76%   
Zymeworks Common Stock competes with SEI Investments, Demant AS, Coca Cola, Golub Capital, and First Trust; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Zymeworks Common competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Zymeworks Common to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Zymeworks Common Correlation with its peers.

Zymeworks Common vs Oaktree Capital Correlation

Very good diversification

The correlation between Zymeworks Common Stock and OAK-PB is -0.34 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Zymeworks Common Stock and OAK-PB in the same portfolio, assuming nothing else is changed.

Moving together with Zymeworks Stock

  0.61UPB Upstream BioPairCorr

Moving against Zymeworks Stock

  0.82OGEN OragenicsPairCorr
  0.74KG Kestrel Group Symbol ChangePairCorr
  0.7XBIO Xenetic BiosciencesPairCorr
  0.7ORIC Oric PharmaceuticalsPairCorr
  0.62ENSC Ensysce BiosciencesPairCorr
As of January 30, 2026, Return On Tangible Assets is expected to decline to -0.26. In addition to that, Return On Capital Employed is expected to decline to -0.35. At present, Zymeworks Common's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 5.02, whereas Non Currrent Assets Other are forecasted to decline to about 5.7 M.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
16.9521.9426.93
Details
Intrinsic
Valuation
LowRealHigh
22.1027.0932.08
Details
Naive
Forecast
LowNextHigh
16.6021.5826.57
Details
10 Analysts
Consensus
LowTargetHigh
32.4135.6239.53
Details

Zymeworks Common Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Zymeworks Common and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Zymeworks and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Zymeworks Common Stock does not affect the price movement of the other competitor.

High positive correlations

BWA
+ 0.91
SEIC
OAK-PB
+ 0.64
WILLF
CCHBF
+ 0.62
SEIC
OAK-PB
+ 0.58
ORIC
BWA
+ 0.56
CCHBF
ORIC
+ 0.54
WILLF
  

High negative correlations

ORIC
- 0.61
CCHBF
ORIC
- 0.46
SEIC
BWA
- 0.4
NFTY
BCRD
- 0.4
CCHBF
NFTY
- 0.39
CCHBF
BWA
- 0.33
ORIC

Risk-Adjusted Indicators

There is a big difference between Zymeworks Stock performing well and Zymeworks Common Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Zymeworks Common's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare Zymeworks Common Stock and related stocks such as SEI Investments, Demant AS, and Coca Cola HBC Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AGraham Number
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
20102011201220132014201520162017201820192020202120222023202420252026
SEIC3.8 M205 M206.8 M288.1 M318.7 M331.7 M333.8 M404.4 M505.9 M501.4 M447.3 M546.6 M475.5 M462.3 M581.2 M668.4 M701.8 M
GBDC59 K31.8 M46.5 M65.4 M70.8 M69.2 M82.3 M82 M(18.6 M)54.9 M340.3 M153.4 M258.6 M273.8 M396.8 M456.3 M479.1 M
ORIC(22 M)(22 M)(22 M)(22 M)(22 M)(22 M)(22 M)(22 M)(21.4 M)(26.9 M)(73.7 M)(77.7 M)(89.1 M)(100.7 M)(127.8 M)(115.1 M)(109.3 M)
BWA(12.1 M)550.1 M500.9 M624.3 M655.8 M609.7 M118.5 M439.9 M930.7 M746 M500 M537 M944 M625 M338 M388.7 M335.4 M

Zymeworks Common Stock and related stocks such as SEI Investments, Demant AS, and Coca Cola HBC Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Zymeworks Common Stock financial statement analysis. It represents the amount of money remaining after all of Zymeworks Common Stock operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Zymeworks Common Competitive Analysis

The better you understand Zymeworks Common competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Zymeworks Common's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Zymeworks Common's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ZYME SEIC WILLF CCHBF GBDC NFTY ORIC BCRD BWA OAK-PB
 0.76 
 22.55 
Zymeworks
 2.25 
 88.04 
SEI
 2.50 
 36.53 
Demant
 0.00 
 51.60 
Coca
 0.07 
 13.55 
Golub
 0.25 
 56.24 
First
 6.19 
 10.30 
Oric
 0.66 
 7.50 
Blueone
 3.17 
 47.38 
BorgWarner
 1.12 
 21.61 
Oaktree
Market Volatility
(90 Days Market Risk)
Not too volatile
Very steady
Very steady
Very steady
Very steady
Very steady
Somewhat reliable
Dangerous
Very steady
Very steady
Market Performance
(90 Days Performance)
Mild
Fair
Good
Fair
Weakest
Weakest
Weakest
Soft
Fair
Soft
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Tiny
Low
Small
Low
Low
High
High
Tiny
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Over Valued
Over Valued
Fairly Valued
Under Valued
Fairly Valued
Under Valued
Over Valued
Under Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Strong Buy
Buy
Not Available
Not Available
Buy
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Buy
Strong Sell
Sell
Cautious Hold
Hold
Sell
Strong Sell
Strong Hold
Sell
Current Ratio
3.29
4.43
0.78
1.02
3.33
N/A
18.72
1.32
1.72
N/A
Net Asset
463.09 M
2.68 B
29.86 B
8.51 B
8.98 B
43.42 M
274.14 M
447.11 K
13.99 B
14.4 M
Profit Margin
-0.47
0.31
0.11
N/A
0.43
N/A
N/A
N/A
0.0095
N/A
EBITDA
(108.62 M)
822.55 M
4.3 B
1.13 B
1.09 M
N/A
(126.74 M)
(485.88 K)
1.32 B
1.01 B
Operating Margin
-0.8
0.28
0.16
N/A
0.79
N/A
N/A
-15.48
0.0841
N/A
Current Valuation
1.45 B
9.57 B
7.98 B
10.17 B
8.45 B
N/A
785.5 M
84.72 M
12.25 B
N/A
Price To Book
5.26
4.32
5.49
2.9
0.9
N/A
2.63
495.8
1.73
N/A
Retained Earnings
(830.34 M)
758 M
N/A
2.9 B
(48.82 M)
N/A
(562.77 M)
N/A
6.41 B
N/A
Current Asset
N/A
1 B
N/A
2.51 B
N/A
N/A
N/A
N/A
838.3 M
N/A
Five Year Return
N/A
1.18
N/A
N/A
7.8
8.5
N/A
N/A
1.67
N/A
One Year Return
N/A
N/A
N/A
N/A
N/A
1.9
N/A
N/A
N/A
N/A
Beta
1.3
0.97
0.93
0.93
0.44
0.49
1.36
1.15
1.05
N/A
Number Of Employees
263
5.07 K
20.57 K
33 K
N/A
646
106
1
38.3 K
N/A
Equity Positions Weight
N/A
N/A
N/A
N/A
N/A
99.41
N/A
N/A
N/A
N/A
Shares Outstanding
74.84 M
122.44 M
223.18 M
366.73 M
266.01 M
N/A
97.39 M
10.34 M
213.93 M
N/A
Three Year Return
N/A
N/A
N/A
N/A
N/A
8.6
N/A
N/A
N/A
N/A
Cash Flow From Operations
(110.04 M)
622.34 M
2.62 B
1.14 B
(113.59 M)
N/A
(112.66 M)
(452.47 K)
1.35 B
(2.73 B)
Annual Yield
N/A
0.0117
N/A
0.0299
0.12
N/A
N/A
N/A
0.0141
0.0363
Total Debt
18.51 M
32.13 M
6.1 B
2.45 B
4.9 B
N/A
3.18 M
43.76 K
4.34 B
7.82 B
Return On Equity
-0.18
0.29
0.28
0.16
0.0942
N/A
-0.4
-5.96
0.0304
N/A
Z Score
N/A
N/A
0.6
1.8
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.0998
0.14
0.071
0.0599
0.0486
N/A
-0.25
-1.01
0.0544
N/A
Number Of Shares Shorted
3.82 M
1.49 M
N/A
N/A
5.58 M
N/A
21.14 M
N/A
11.62 M
N/A
Book Value Per Share
4.26
19.58
38.36
8.95
14.97
N/A
4.18
-0.003
28.0
N/A
Current Liabilities
N/A
224.48 M
N/A
2.61 B
N/A
N/A
N/A
N/A
484 M
N/A
Total Asset
463.09 M
2.68 B
29.86 B
8.51 B
8.98 B
43.42 M
274.14 M
447.11 K
13.99 B
14.4 M
Debt To Equity
0.14
0.015
1.64
1.02
1.21
N/A
0.054
0.35
0.59
N/A
Short Ratio
4.28
2.45
N/A
N/A
2.68
N/A
12.1
N/A
3.18
N/A
Target Price
35.62
98.83
N/A
N/A
15.0
N/A
21.0
N/A
50.54
N/A
Last Dividend Paid
N/A
0.98
N/A
N/A
1.56
0.13
N/A
N/A
0.5
2.97
Shares Owned By Institutions
99.03
74.4
18.48
28.5
46.53
N/A
93.29
N/A
99.01
N/A
Market Capitalization
1.7 B
10.64 B
7.02 B
8.93 B
3.61 B
N/A
1.07 B
87.86 M
10.45 B
6.1 B
Price To Earning
-2.36
19.7
36.39
17.76
21.96
N/A
N/A
N/A
17.95
12.69
Price To Earnings To Growth
N/A
1.4
1.75
N/A
1.51
N/A
N/A
N/A
1.21
N/A
Price To Sales
12.63
4.74
0.33
1.1
4.14
N/A
N/A
1675.06
0.74
N/A
Net Income
(122.69 M)
581.19 M
2.08 B
547.2 M
376.65 M
N/A
(127.85 M)
(530.83 K)
367 M
1.16 B
Earnings Per Share
-0.85
5.63
1.45
1.47
1.42
N/A
-1.71
-0.051
0.71
N/A
Shares Owned By Insiders
0.97
16.76
60.87
46.89
1.37
N/A
6.71
87.07
0.99
N/A
Revenue
76.3 M
2.13 B
19.7 B
7.17 B
802.73 M
N/A
N/A
72.2 K
14.08 B
1.45 B
Working Capital
212.16 M
1.17 B
N/A
(106 M)
N/A
N/A
237.4 M
N/A
2.88 B
N/A
Ten Year Return
N/A
N/A
N/A
N/A
N/A
10.3
N/A
N/A
N/A
N/A
Cash And Equivalents
241.83 M
791.44 M
1.24 B
1.77 B
85.2 M
N/A
227.06 M
167.13 K
2.09 B
N/A
Cash Per Share
4.18
5.87
5.46
4.84
0.5
N/A
5.74
0.02
5.27
N/A
Gross Profit
(8.35 M)
1.77 B
14.67 B
3.14 B
870.78 M
N/A
N/A
17.42 K
2.6 B
601.12 M
Day Typical Price
22.47
87.39
36.53
51.6
13.62
56.19
10.91
7.5
47.9
21.49
Accumulation Distribution
0.0106
0.022
N/A
N/A
0.0196
0.0025
0.15
N/A
0.0317
324.8
Market Facilitation Index
0.24
1.94
N/A
N/A
0.27
0.14
1.82
N/A
1.55
0.0
Daily Balance Of Power
0.7083
1.0
9.2 T
0.0
0.037
1.0
(0.37)
0
(1.00)
0.5854
Period Momentum Indicator
0.17
1.94
0.89
N/A
0.01
0.14
(0.68)
(0.05)
(1.55)
0.24
Rate Of Daily Change
1.01
1.02
1.02
1.0
1.0
1.0
0.94
0.99
0.97
1.01
Day Median Price
22.43
87.07
36.53
51.6
13.66
56.17
11.21
7.5
48.16
21.44
Price Action Indicator
0.21
1.94
0.45
N/A
(0.10)
0.14
(1.25)
(0.03)
(1.55)
0.29
Relative Strength Index
47.55
59.24
83.83
73.31
47.28
41.96
47.65
46.71
54.0
61.24
Coefficient Of Variation
1057.8
1013.34
(34,770)
800.76
(4,054)
(999.54)
(3,357)
1892.3
941.76
3236.72
Mean Deviation
2.91
0.9576
0.4268
0.5302
0.702
0.5583
2.81
4.9
1.23
0.5418
Jensen Alpha
0.4698
0.0605
(0)
0.1683
(0.04)
(0.1)
(0.14)
1.26
0.1081
0.0104
Total Risk Alpha
0.1057
0.026
(0.11)
0.0639
(0.09)
(0.13)
(0.40)
(0.34)
0.0509
(0.04)
Sortino Ratio
0.1271
0.0548
N/A
N/A
N/A
N/A
N/A
0.057
0.0724
(0.05)
Downside Variance
9.76
1.43
N/A
N/A
N/A
N/A
N/A
258.41
2.78
0.6127
Standard Deviation
4.85
1.28
1.38
1.36
0.8799
0.7051
3.84
18.51
1.71
0.7841
Kurtosis
18.12
2.07
27.37
13.13
0.1217
0.4636
1.49
49.39
1.32
5.02
Potential Upside
5.4
2.1
2.32
3.2
1.37
0.8215
6.63
2.41
3.51
1.34
Treynor Ratio
(1.07)
0.1065
0.0768
(1.01)
(0.13)
(0.25)
(0.32)
(0.17)
0.1381
0.1922
Maximum Drawdown
36.09
7.41
8.87
11.95
3.53
3.79
15.34
187.41
8.11
4.82
Variance
23.5
1.65
1.89
1.86
0.7743
0.4972
14.77
342.53
2.94
0.6148
Market Risk Adjusted Performance
(1.06)
0.1165
0.0868
(1.00)
(0.12)
(0.24)
(0.31)
(0.16)
0.1481
0.2022
Risk Adjusted Performance
0.0771
0.076
0.0026
0.0953
(0.02)
(0.07)
(0.01)
0.048
0.0829
0.0232
Skewness
3.24
0.4261
(3.73)
1.06
0.0534
(0.12)
0.5166
6.21
0.0107
(0.90)
Semi Deviation
2.71
1.08
N/A
N/A
N/A
N/A
N/A
7.12
1.55
0.7552
Information Ratio
0.0819
0.051
(0.05)
0.0799
(0.09)
(0.19)
(0.05)
0.0495
0.0704
(0.05)
Value At Risk
(4.49)
(1.49)
(1.28)
N/A
(1.31)
(0.99)
(4.48)
(8.76)
(2.90)
(0.99)
Expected Short fall
(3.41)
(1.03)
N/A
N/A
N/A
N/A
N/A
(12.38)
(1.34)
(0.62)
Downside Deviation
3.12
1.2
N/A
N/A
N/A
N/A
N/A
16.08
1.67
0.7828
Semi Variance
7.35
1.17
N/A
N/A
N/A
N/A
N/A
50.71
2.41
0.5703

Zymeworks Common Competition Performance Charts

Five steps to successful analysis of Zymeworks Common Competition

Zymeworks Common's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Zymeworks Common Stock in relation to its competition. Zymeworks Common's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Zymeworks Common in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Zymeworks Common's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Zymeworks Common Stock, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Zymeworks Common position

In addition to having Zymeworks Common in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Long Short Funds Thematic Idea Now

Long Short Funds
Long Short Funds Theme
Funds or Etfs that are designed to hedge away market risk by investing in combination of bonds, stocks, derivative instruments as well as short positions to maximize returns irrespective of market conditions. The Long Short Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long Short Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:
How To Invest In Zymeworks
Details
Is Zymeworks Stock a good investment?
Details
What is Zymeworks Common's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Zymeworks Common Correlation with its peers.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Will Biotechnology sector continue expanding? Could Zymeworks diversify its offerings? Factors like these will boost the valuation of Zymeworks Common. Anticipated expansion of Zymeworks directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Zymeworks Common data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.85)
Revenue Per Share
1.788
Quarterly Revenue Growth
0.726
Return On Assets
(0.1)
Return On Equity
(0.18)
Zymeworks Common Stock's market price often diverges from its book value, the accounting figure shown on Zymeworks's balance sheet. Smart investors calculate Zymeworks Common's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Zymeworks Common's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY